Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Century Therapeutics, Inc. - Common Stock (NQ:IPSC)

0.6198 +0.0197 (+3.28%)
Streaming Delayed Price Updated: 3:13 PM EDT, Oct 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Century Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Reports Flat Loss in Fiscal Q2
Via The Motley Fool
4 Analysts Have This To Say About Century Therapeutics
 
Via Benzinga
5 Analysts Assess Century Therapeutics: What You Need To Know
 
Via Benzinga
Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Century Therapeutics, Inc.
Via GlobeNewswire
Monday's after hours session: top gainers and losers
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting
From Century Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025
From Century Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
Demystifying Century Therapeutics: Insights From 4 Analyst Reviews
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Stages Highest Single Day Move In 11 Months As Casdin Capital Bumps Its Stake To 5.4%
 
Via Benzinga
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer
From Century Therapeutics, Inc.
Via GlobeNewswire
Robinhood To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
IPSC Stock Earnings: Century Therapeutics Beats EPS for Q2 2024
IPSC stock results show that Century Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
From Century Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.